Xenon Pharmaceuticals Inc

NASDAQ:XENE  
30.80
+0.38 (+1.25%)
Products

Xenon Pharmaceuticals Announces Positive Outcome Of End-Of-Phase 2 Meeting With The FDA

Published: 06/21/2022 13:52 GMT
Xenon Pharmaceuticals Inc (XENE) - Xenon Pharmaceuticals Announces Positive Outcome of End-of-phase 2 Meeting With the FDA.
Xenon Pharma - Plans to Initiate Xen1101 Phase 3 Clinical Trial in an Additional Epilepsy Indication of Primary Generalized Tonic Clonic Seizures.
Xenon Pharmaceuticals Inc - Xen1101 Phase 3 Program for Treatment of Focal Onset Seizures to Be Initiated in Second Half of 2022.
Xenon Pharmaceuticals -plans to Initiate Xen1101 Phase 3 Clinical Trial in Additional Epilepsy Indication of Primary Generalized Tonic Clonic Seizures.
Xenon Pharmaceuticals Inc - Outcome of Eop2 Meeting Supports Advancement of Xen1101 Into Phase 3 Clinical Development.
Xenon-new Drug Application for Xen1101 Expected to Be Submitted After Completing First Phase 3 Clinical Trial With Completed Phase 2b Clinical Trial.
Xenon Pharmaceuticals Inc - Plans to Submit an NDA Upon Completion of First Xen1101 Phase 3 Clinical Trial 'x-tole2'.